Risk factors for type 2 diabetes mellitus preceded by β-cell dysfunction, insulin resistance, or both in older adults

American Journal of Epidemiology

Volumn 177, Issue 12, 2013, Pages 1418-1429

  Imamura, Fumiaki ^a   Mukamal, Kenneth J ^b,c   Meigs, James B ^c   Luchsinger, José A ^d   Ix, Joachim H ^e,f   Siscovick, David S ^g   Mozaffarian, Dariush ^a,h  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

aging; diabetes mellitus; incidence; insulin resistance; insulin secreting cells; risk factors

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGING; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CYTOLOGY; DIABETES; DISEASE INCIDENCE; FAT; HEALTH RISK; HORMONE; OBESITY; RISK FACTOR;

AGED; ALCOHOL CONSUMPTION; ARTICLE; HUMAN; INCIDENCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS INSUFFICIENCY; PANCREAS ISLET BETA CELL DYSFUNCTION; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

CALIFORNIA; MARYLAND; NORTH CAROLINA; PENNSYLVANIA; UNITED STATES;

EID: 84878886362     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws440     Document Type: Article

References (50)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34(suppl 1): S62-S69.
2. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32(1):193-203.
3. Heine RJ, Diamant M, Mbanya JC, et al. Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? BMJ. 2006;333(7580):1200-1204.
4. Wilson PW, Meigs JB, Sullivan L, et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167(10):1068-1074.
5. Song Y, Manson JE, Tinker L, et al. Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women. Diabetes Care. 2007;30(7):1747-1752.
6. Haffner SM, Kennedy E, Gonzalez C, et al. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care. 1996;19(10):1138- 1141.
7. Lorenzo C,Wagenknecht LE, D'Agostino RB, et al. Insulin resistance, cell dysfunction, and conversion to type 2 diabetes in a multiethnic population. Diabetes Care. 2010; 33(1):67-72.
8. Pradhan AD, Manson JE, Meigs JB, et al. Insulin, proinsulin, proinsulin:insulin ratio, and the risk of developing type 2 diabetes mellitus in women. Am J Med. 2003;114(6):438-444.
9. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of noninsulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med. 1993;329(27):1988-1992.
10. Bonora E, Kiechl S,Willeit J, et al. Population-based incidence rates and risk factors for type 2 diabetes in white individuals. Diabetes. 2004;53(7):1782-1789.
11. Hanley AJ, D'Agostino R Jr,Wagenknecht LE, et al. Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the Insulin Resistance Atherosclerosis Study. Diabetes. 2002;51(4):1263-1270.
12. Tabák AG, Jokela M, Akbaraly TN, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II Study. Lancet. 2009;373(9682):2215-2221.
13. Haffner SM, Mykkanen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101(9):975-980.
14. Birkeland KI, Kilhovd B, Thorsby P, et al. Heterogeneity of non-insulin-dependent diabetes expressed as variability in insulin sensitivity, cell function and cardiovascular risk profile. Diabet Med. 2003;20(1):37-45.
15. Meneilly GS, Elliott T, Tessier D, et al. NIDDM in the elderly. Diabetes Care. 1996;19(12):1320-1325.
16. Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med. 1997;103(2):152-162.
17. Haffner SM, D'Agostino R, Mykkänen L, et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 1999;22(4):562-568.
18. Mykkanen L, Haffner SM, Ronnemaa T, et al. Low insulin sensitivity is associated with clustering of cardiovascular disease risk factors. Am J Epidemiol. 1997;146(4):315-321.
19. Hanley AJ,Williams K, Stern MP, et al. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease. Diabetes Care. 2002;25(7): 1177-1184.
20. Festa A, Hanley AJG, Tracy RP, et al. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation. 2003;108(15): 1822-1830.
21. Ferrannini E, Balkau B, Coppack SW, et al. Insulin resistance, insulin response, and obesity as indicators of metabolic risk. J Clin Endocrinol Metab. 2007;92(8):2885-2892.
22. Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabetes Care. 2005;28(10):2472-2479
23. Ferrannini E, Camastra S, Gastaldelli A, et al. Beta-cell function in obesity. Diabetes. 2004;53(suppl 3):S26-S33.
24. Hanley AJ,Wagenknecht LE, D'Agostino RB Jr, et al. Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes. 2003;52(11):2740-2747.
25. Iozzo P, Beck-Nielsen H, Laakso M, et al. Independent influence of age on basal insulin secretion in nondiabetic humans. J Clin Endocrinol Metab. 1999;84(3):863-868.
26. Chen C-H, Tsai S-T, Chou P. Correlation of fasting serum C-peptide and insulin with markers of metabolic syndrome-X in a homogeneous Chinese population with normal glucose tolerance. Int J Cardiol. 1999;68(2):179-186.
27. Yudkin JS, May M, Elwood P, et al. Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study. Diabetologia. 2002;45(3):327-336.
28. Oh J-Y, Barrett-Connor E,Wedick NM. Sex differences in the association between proinsulin and intact insulin with coronary heart disease in nondiabetic older adults: the Rancho Bernardo Study. Circulation. 2002;105(11):1311-1316.
29. Rönnemaa T, Laakso M, Puukka P, et al. Atherosclerotic vascular disease in middle-aged, insulin-treated, diabetic patients. Association with endogenous insulin secretion capacity. Arterioscler Thromb Vasc Biol. 1988;8(3):237-244.
30. Reaven GM, Chen YD, Hollenbeck CB, et al. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab. 1993;76(1):44-48.
31. Yudkin JS, Denver AE, Mohamed-Ali V, et al. The relationship of concentrations of insulin and proinsulin-like molecules with coronary heart disease prevalence and incidence. A study of two ethnic groups. Diabetes Care.2002;45(3):327-336.
32. Fritsche A, Madaus A, Stefan N, et al. Relationships among age, proinsulin conversion, and ?-cell function in nondiabetic humans. Diabetes. 2002;51(suppl 1):S234-S239.
33. Fried LP, Borhani NO, Enright P, et al. The cardiovascular health study: design and rationale. Ann Epidemiol. 1991;1(3): 263-276.
34. Psaty BM, Lee M, Savage PJ, et al. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. J Clin Epidemiol.1992;45(6):683-692
35. Ives DG, Fitzpatrick AL, Bild DE, et al. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol. 1995;5(4):278-285.
36. Biggs ML, Mukamal KJ, Luchsinger JA, et al. Association between adiposity in midlife and older age and risk of diabetes in older adults. JAMA. 2010;303(24):2504-2512.
37. Cushman M, Cornell ES, Howard PR, et al. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;41(2):264-270.
38. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-1495.
39. Festa A,Williams K, Hanley AJG, et al. Cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes. Diabetes. 2008;57(6):1638-1644.
40. Herzberg-Schäfer SA, Staiger H, Heni M, et al. Evaluation of fasting state-/oral glucose tolerance test-derived measures of insulin release for the detection of genetically impaired cell function. PLoS One. 2010;5(12):e14194.
41. Meigs JB, Rutter MK, Sullivan LM, et al. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007; 30(5):1219-1225.
42. Mozaffarian D, Kamineni A, Carnethon M, et al. Lifestyle risk factors and new-onset diabetes mellitus in older adults: the cardiovascular health study. Arch Intern Med. 2009;169(8): 798-807.
43. Geffken DF, CushmanM, Burke GL, et al. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol. 2001;153(3):242-250.
44. Kumanyika S, Tell GS, Fried L, et al. Picture-sort method for administering a food frequency questionnaire to older adults. J Am Diet Assoc. 1996;96(2):137-144.
45. Pepe MS, Anderson GL. A cautionary note on inference for marginal regression models with longitudinal data and general correlated response data. Commun Stat Simul Comp. 1994; 23(4):939-951.
46. Lunn M, Don M. Applying Cox regression to competing risks. Biometrics. 1995;51(2):524-532.
47. Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL, et al. Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes. 2000;49(1):32-38.
48. Listenberger LL, Han X, Lewis SE, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci USA. 2003;100(6):3077-3082.
49. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6): 393-403.
50. Kitabchi AE, TemprosaM, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: effects of lifestyle intervention and metformin . Diabetes. 2005;54(8):2404-2414.